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Lymphoid  precursors  migrate  from  liver  and 
bone marrow to thymus, where they develop into 
CD4+ or CD8+ T cells through a choreographed 
set of intrathymic migrations (Takahama, 2006; 
Petrie and Zúñiga-Pflücker, 2007; Bunting et al., 
2011;  Love  and  Bhandoola,  2011)  that  ac-
company maturation of the TCR, followed 
by positive and negative selection of antigen 
specificity (von Boehmer et al., 2003). Mature 
thymocytes enter the venous circulation and 
traffic to secondary lymphoid organs (SLOs), 
awaiting an antigenic stimulus (Drennan et al., 
2009; Bunting et al., 2011; Love and Bhandoola, 
2011). T cell trafficking is critical to immune 
surveillance and to the generation of an effective 
immune response (Bromley et al., 2008). This 
trafficking is mediated by a set of chemotactic 
receptors, adhesion molecules, the cellular actin 
network, and its regulators.
Recent work has established the Mst1 kinase 
as an important regulator of T cell adhesion, 
migration, proliferation, and apoptosis (Zhou 
et al., 2008; Choi et al., 2009; Dong et al., 
2009; Katagiri et al., 2009). The murine Mst1 
and Mst2 kinases are most abundant in tissues 
of the lymphoid system, and mice lacking Mst1 
exhibit a variety of T cell abnormalities. Among 
the most prominent is an 50% reduction in 
the number of CD62LhiCD44lo mature naive 
T cells in SLOs, with little change in the num-
ber of CD62LloCD44hi effector/memory T cells; 
available evidence supports several contribu-
tory mechanisms. Whereas thymic develop-
ment in Mst1-null mice is largely unaltered, 
single-positive  (SP)  thymocytes  are  modestly 
increased and show a diminished egress in vivo 
after labeling with FITC as well as in vitro in 
response to CCL19, CCL21, CXCL12, and 
CCL25 (Dong et al., 2009). In addition, al-
though selectin-mediated rolling of Mst1-null 
naive T cells on endothelium is intact, their 
ability to adhere to high endothelial venules 
and enter peripheral LNs is reduced by 65%, 
a defect largely attributable to their inability to 
activate the integrins LFA-1 and MAdCAM-1 
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The Mst1 kinase is an important regulator of murine T cell adhesion, migration, prolifera-
tion, and apoptosis. In this study, we analyze mice lacking both Mst1 and Mst2 in hemato-
poietic cells. Compared with wild-type mice, these double knockout (DKO) mice exhibit a 
severe reduction in the number of mature T cells in the circulation and in secondary lym-
phoid organs (SLOs). CD4+CD8 and CD4CD8+ single-positive (SP) thymocytes in DKO 
mice resemble mature T cells of wild-type mice but undergo excessive apoptosis, and their 
egress from the thymus is reduced by >90%. Even when placed directly in the circulation, 
DKO SP thymocytes failed to enter SLOs. In SP thymocytes, deficiency of Mst1 and Mst2 
abolished sphingosine-1 phosphate– and CCL21-induced Mob1 phosphorylation, Rac1 and 
RhoA GTP charging, and subsequent cell migration. When phosphorylated by Mst1 or Mst2, 
Mob1 binds and activates the Rac1 guanyl nucleotide exchanger Dock8, which is abundant 
in the thymus. Thus, the Mst1 and Mst2 kinases control Rho GTPase activation and the 
migratory responses of SP thymocytes.
© 2012 Mou et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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changes in lymphocyte numbers in any compartment, nor did 
Mst2 deletion alter the abundance of Nore1b/RAPL/Rassf5b 
or the phosphorylation of Mob1 in the thymus (Fig. 1 A). 
Mst1-null/Mst2ff mice were crossed with mice expressing cre 
recombinase driven by a vav promoter (de Boer et al., 2003), 
resulting in inactivation of the Mst2 gene in the entire hema-
topoietic lineage. These mice were born at a normal ratio and 
survived weaning without difficulty. In addition to the loss of 
Mst2, thymic expression of Nore1b in the vav-cre/Mst1-null/
Mst2ff mice (henceforth called Mst1/Mst2vavDKO) was 
essentially eliminated, as was Mob1A/B phosphorylation 
(Fig. 1 A). Peripheral blood counts showed that the number of 
circulating lymphocytes was reduced to <10% of WT in the 
Mst1/Mst2vavDKO mice (Fig. 1 B). The thymus of the Mst1/
Mst2vavDKO mice was slightly smaller than WT, and the   
total numbers of thymocytes were not significantly decreased 
(Fig. 1, C and D). As regards T cells, the number of circulating 
CD4+ and CD8+ cells in the Mst1/Mst2vavDKO was <2% 
and 1%, respectively, of WT levels. Similarly, CD4+ and CD8+ 
T cell numbers in the spleen and LNs were also reduced by 
>98% (Fig. 1 D). The morphology of the SLOs reflects the se-
vere depletion of peripheral T cells; there was a complete loss 
of white pulp in the spleens of the Mst1/Mst2vavDKO mice, 
and their LNs were atrophic (not depicted). The preserved 
number of CD4+ and CD8+ SP thymocytes together with the 
severe deficiency of peripheral T cells indicates that T cell de-
velopment in the Mst1/Mst2vavDKO mice has occurred suc-
cessfully, but egress from the thymus, which is partially impaired 
in Mst1-null mice (Dong et al., 2009), is inhibited to a much 
greater extent in the Mst1/Mst2vavDKO mice.
Transgenic WT but not kinase-inactive Mst1 restores 
peripheral T cell number in Mst1/Mst2 DKO mice
The deficiency of peripheral T cells seen in the Mst1-null and 
especially in the Mst1/Mst2vavDKO mice can be entirely cor-
rected by restoration of a catalytically active Mst1 kinase. Thus, 
transgenic expression of an Mst1 cDNA driven by the CD2 
promoter in Mst1-null and Mst1/Mst2vavDKO mice (Fig. 2 A) 
restored to WT levels the number and balance of mature, 
naive CD4+ and CD8+ T cells in the spleen (Fig. 2, B and C). 
The abundance of Nore1b was also restored to near-WT 
levels, as was the extent of phosphorylation of Mob1A/B 
(Fig. 2 A). In contrast, transgenic expression of a catalytically 
inactive, ATP site Mst1 mutant (Mst1[K59R]) in Mst1-null 
mice, although restoring Nore1b expression to normal, further 
reduced Mob1A/B phosphorylation and worsened the defi-
ciency of peripheral naive T cells toward the levels seen in the 
Mst1/Mst2vavDKO mice (Fig. 2, B and C). Thus, it is the lack 
of Mst1 catalytic activity rather than of Nore1b that underlies 
the phenotype of Mst1 and Mst1 + Mst2 deficiency in the   
T cell compartment.
Mst1 and Mst2 abundance and activity increase  
markedly in SP thymocytes of WT mice
Mst1 and Mst2 abundance was low in CD4+CD8+ double-
positive (DP) WT thymocytes and increased markedly and 
in response to chemokines (Katagiri et al., 2009). Mst1-null   
T cells also show diminished migration on immobilized che-
mokines and within explanted LNs. As first shown by Katagiri 
et al. (2006), Mst1 in T cells is found in a 1:1 complex with the 
RAPL/Nore1B/Rassf5B  polypeptide,  a  Rap1-GTP–binding 
protein (Praskova et al., 2004; Avruch et al., 2009). Chemokine 
or T cell receptor activation promotes Rap1-GTP charging and 
recruits the RAPL–Mst1 complex to the leading edge. There 
the RAPL–Mst1 complex binds to and clusters LFA-1; T cells 
deficient in either RAPL (Katagiri et al., 2004) or Mst1 (Zhou 
et al., 2008; Katagiri et al., 2009) do not exhibit LFA-1 cluster-
ing in response to chemokines or TCR activation. The bio-
chemical mechanism by which Mst1 promotes LFA-1 activation 
is not known.
Mst1-deficient naive T cells also show a greatly enhanced pro-
liferative response to TCR stimulation and higher levels of on-
going apoptosis in vivo, another likely contributor to their low 
numbers in vivo. Notably, the levels of Mst1 polypeptide are re-
duced by 10-fold in the normal transition from naive to effector 
cell. Thus, Mst1 is a negative regulator of the commitment of 
naive T cells to a proliferative response upon TCR activation 
(Zhou et al., 2008). Mst1 is homologous to the Drosophila melano-
gaster kinase hippo, which inhibits cell proliferation in response 
to cell–cell contact by negative regulation of the transcriptional 
co-activator yorkie (Pan, 2010; Halder and Johnson, 2011). The 
mechanism of the antiproliferative effect of Mst1 in naive T cells 
is unknown, inasmuch as the mammalian yorkie orthologue Yap1 
does not participate in the proliferative response of naive T cells to 
TCR/CD28 co-stimulation (Zhou et al., 2008).
In this study, we characterize the effect of the combined 
elimination of Mst1 and Mst2 from the lymphoid compartment; 
whereas T cell development proceeds normally, the ability of SP 
thymocytes to exit is severely inhibited, and they exhibit a high 
rate of intrathymic apoptosis. Chemokines and sphingosine-1 
phosphate (S1P) fail to activate rho family small GTPases or 
polarize the actin cytoskeleton in the Mst1/Mst2-deficient SP 
thymocytes, and their migratory responses are profoundly in-
hibited. The phosphorylation of Mst1/Mst2 substrates Mob1A 
and Mob1B (see Materials and methods for a description of 
Mob1A/B nomenclature) is lost entirely. The 25-kD noncatalytic 
Mob1A/B polypeptides, consequent to their phosphorylation 
by Mst1/Mst2, are known to bind and activate ndr family 
kinases (Praskova et al., 2008; Hergovich, 2011). We find that 
phospho-Mob1A/B also bind specifically and activate the Dock8 
guanyl nucleotide exchanger. In thymocytes, CCL19 stimulates 
thymocyte Mob1A/B phosphorylation in an Mst1/Mst2- 
dependent manner and promotes phospho-Mob1A/B binding to 
endogenous Dock8. We propose that the inability of the Mst1/
Mst2-deficient T cells to recruit Dock8 contributes to the failure 
of rho GTPase activation, actin regulation, and thymic egress.
RESULTS
Deletion of Mst1 and Mst2 from the lymphoid  
compartment reduces peripheral T cell number by 98%
In contrast to the reduced numbers of naive T cells seen with 
deletion of Mst1, a global deletion of murine Mst2 caused no JEM Vol. 209, No. 4 
Article
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Mst2 activation loops (identical in amino acid sequence) and 
by the extent of phosphorylation of Mob1A/B at the sites 
catalyzed  specifically  by  Mst1  and  Mst2  (Praskova  et  al., 
2008; Zhou et al., 2008, 2009). FoxO1 and FoxO3 are other 
documented substrates of Mst1/Mst2 (Lehtinen et al., 2006); 
however, neither the abundance of FoxO3 nor the extent   
of FoxO1/3 phosphorylation at the site catalyzed by Mst1/
Mst2 was altered in SP as compared with DP thymocytes. 
to a similar extent in CD4+ and CD8+ SP thymocytes; the 
abundance of Nore1b increased in parallel (Fig. 3 A). The 
low expression of Mst1 and Mst2 in DP as compared with 
SP thymocytes suggests that these kinases are likely to have 
little or no role in thymocyte development up through the 
DP stage. The activity of Mst1/Mst2 was also low in the DP 
thymocytes and much higher in the SP thymocytes, as indi-
cated by the increase in the phosphorylation of the Mst1 and 
Figure 1.  Deletion of Mst1 and Mst2 causes lymphopenia. (A) Thymic extracts from WT (Vav-Cre+Mst1+/+Mst2+/+ mice) Mst1-null (KO), and Vav-
Cre+Mst1/Mst2ff (DKO) mice were analyzed by Western blot. T12 followed by P indicates phosphorylation. (B) White blood cell (WBC) and circulating 
lymphocyte counts in mice described in A. Each dot represents an individual mouse, and horizontal bars indicate the mean. (C and D) Single cell suspen-
sions from the thymus, spleen, LN, and peripheral blood were analyzed by flow cytometry. (C) Representative dot plots. (D) Absolute numbers of the indi-
cated populations. Comparisons were performed using the Student’s t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Each bar represents combined results 
from three mice of the indicated genotype. Error bars indicate ±SEM.744 Mst1 and Mst2 control thymocyte egress | Mou et al.JEM Vol. 209, No. 4 
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to 44.3% and 26.3%, respectively (Fig. 4 A, bottom). This 
increase in S1pr1 surface expression was paralleled by an in-
creased level of S1pr1 messenger RNA in the thymus of 
Mst1-null and Mst1/Mst2vavDKO mice (Fig. 4 B). S1pr1 
surface expression was severely reduced by pretreatment of 
both WT (Fig. 4, A and C) and Mst1/Mst2vavDKO mice 
with FTY720 (Fig. 4 C).
In addition to the increased numbers of SP thymocytes 
expressing S1pr1 and Qa-2, other indicators of the hyper-
maturation of CD4+ SP Mst1/Mst2vavDKO thymocytes 
were their higher levels of Qa-2 as well as CD62L expression 
and the substantial reduction in CD69 and CD24 expression 
(Fig. 4 D). The similarity of the hypermaturation phenotype 
of  Mst1/Mst2vavDKO  SP  thymocytes  to  that  elicited  by 
FTY720 treatment of WT mice impelled us to measure S1P 
levels (Sensken et al., 2010), which we found to be similar in 
plasma (range 2.03–3.96 µM) and thymic extracts (range 0.0–0.5 
pmol/µg protein) of WT and Mst1/Mst2vavDKO mice. In 
addition, the Mst1/Mst2vavDKO SP thymocytes exhibited 
no significant change from WT in their expression of the 
chemokine receptors CCR7, CXCR3, CXCR4, and CCR5, 
as well as the integrins CD11b and LFA-1 (Fig. 4 D). Thus, 
the  DKO  thymocytes  exhibit  uninterrupted  maturation 
toward the phenotype of mature naive peripheral T cells, 
similar  to  that  seen  with  WT  thymocytes  whose  thymic 
egress is blocked selectively by down-regulation of the S1P 
receptor. The few peripheral CD4+ T cells in the Mst1/
Mst2vavDKO mice exhibited a CD62LloCD44hi phenotype, 
without elevated expression of the activation markers CD69 
or CD25 (Fig. 4 E).
Thymic egress and LN entry of Mst1/Mst2-deficient  
SP thymocytes are severely reduced
The Mst1/Mst2vavDKO mice experience a very high rate of 
infection, suggesting functional deficits in myeloid lineages in 
addition to T cells. To avoid confounding interactions and 
in view of the relatively well preserved developmental pro-
file of thymic SP T cells in the Mst1/Mst2vavDKO mice, we 
crossed the Mst1-null/Mst2ff mice with mice expressing Cre 
driven by the distal promoter of the Lck gene, which is ex-
pressed at a later stage of development (Zhang et al., 2005). 
As with the Mst1/Mst2vavDKO mice, the lck-cre/Mst1-
null/Mst2ff (henceforth called Mst1/Mst2lckDKO) mice ex-
hibited a dramatic reduction in peripheral T cells (Fig. 5 A) 
and distortion of thymic architecture (Fig. 5 B); however, the 
number of CD4+ and CD8+ SP cells in the Mst1/Mst2lckDKO 
thymus was significantly increased (Fig. 5 A, top bar graph). 
Similarly, elimination of Mst1 and Mst2 did not alter the 
abundance of Klf2, a transcriptional target of FoxO1/3 and 
itself a transcriptional regulator of CD62L, S1pr1 (S1P re-
ceptor 1), CCR7, and other genes relevant to T cell migra-
tion (Fig. 3 B).
The morphology of the Mst1/Mst2vavDKO thymus is 
subtly altered from normal; the distinctively darker stain-
ing of the cortex as compared with the medulla in the WT 
thymus, which reflects the greater number and density of 
cortical T cells as well as their lesser cytoplasmic content 
(Pearse, 2006), was considerably attenuated (Fig. 3 C), and 
staining for CD4 confirmed that the marked difference in 
cellular abundance/density between the cortex and medulla 
seen in the WT was also attenuated in the Mst1/Mst2vavDKO 
thymus. This alteration in thymic architecture differs from 
the acute effect of FTY720, a superagonist that down-regulates 
S1pr1, whose inhibition of thymic egress is accompanied 
by a thinning of the cortex and a marked expansion of the 
medulla (Yagi et al., 2000). Thus, the geographic distribution 
of CD4+ (SP and DP) cells appears to be abnormal in the 
Mst1/Mst2vavDKO thymus.
Mst1/Mst2-deficient SP thymocytes resemble  
recent thymic emigrants in WT mice
We next examined the developmental profile of the Mst1/
Mst2vavDKO thymocytes. Qa-2 is a nonpolymorphic MHC 
class 1 type molecule expressed late in thymocyte devel-
opment whose abundance increases further after emigration, 
whereas CD24 is highly expressed throughout thymocyte 
development but is greatly diminished on recent thymic 
emigrants and diminishes further in the periphery (Boursalian   
et al., 2004). Inhibition of thymic egress with FTY720 increased 
the fraction of CD4+ SP Qa-2hiCD24lo thymocytes from 27.9   
to 60.9% (Fig. 4 A, top) and their total number from 2 × 106 
to 5.7 × 106 (Fig. 4 A, left bar graph), reflecting the 
continued intrathymic maturation of the CD4+ SP cells 
despite the blockade of egress. In the Mst1/Mst2vavDKO 
thymus, a very similar increase occurred in the percentage 
(Fig. 4 A, top) and number (Fig. 4 A, bar graphs) of CD4+ 
and CD8+ SP cells that exhibited a Qa-2hiCD24lo phenotype 
as compared with that seen with FTY720 treatment of WT 
mice. The S1P receptor subtype S1pr1, which is expressed 
very late in thymocyte development (Carlson et al., 2006), 
was detectable on 13.9% of Qa-2hiCD24loCD4+ and 2.3% of 
Qa-2hiCD24loCD8+ SP WT thymocytes, whereas in the 
Mst1/Mst2vavDKO thymus, the fraction of Qa-2hiCD24loCD4+ 
and Qa-2hiCD24loCD8+ SP cells expressing S1pr1 was increased 
Figure 2.  Mst1 WT and Mst1(KR) transgenic mice. (A) Flag-Mst1(WT) and Flag-Mst1 KR (inactive mutant K59R) expression driven by CD2 promoter 
was confirmed by Western blot of thymic extracts as in Fig. 1. (B) Representative flow cytometric analyses of spleen from Mst1+/+Mst2+/+ (WT), Mst1-null 
(1KO), Mst1-null/Flag-Mst1(WT) (1KO-WT), Mst1-null/Flag-Mst1(KR) (1KO-KR), Vav-Cre+Mst1/Mst2ff (DKO), Vav-Cre+Mst1/Mst2ff/Flag-Mst1(WT) 
(DKO-WT), and Vav-Cre+Mst1/Mst2ff/Mst1(KR) (DKO-KR) mice for CD4+ and CD8+ T cells and their expression level of CD62L and CD44. (C) Total number 
of total CD4+ and CD8+ cells (top), CD44loCD62Lhi (middle), and CD44hiCD62Llo (bottom) in spleen of WT and the various mutant transgenic mice. Com-
parisons used the Student’s t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Each bar represents combined results from three mice of the indicated geno-
type. Error bars indicate ±SEM.
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by  90%  in  the  Mst1/Mst2lckDKO 
mice, demonstrating the substantial fur-
ther  reduction  engendered  by  further 
elimination of Mst2 (Fig. 5 C). Although 
defective thymic egress was the dom-
inant contributor to the low number of 
peripheral Mst1/Mst2lckDKO T cells, 
a second factor was their high rate of 
apoptosis, which in freshly isolated 
Mst1/Mst2lckDKO  SP  thymocytes 
was approximately sevenfold higher 
than in WT SP thymocytes; higher 
apoptosis was also evident in the Mst1/
Mst2lckDKO DP thymocytes (Fig. 5 D). 
As to the mechanisms responsible, be-
cause  the  Mst1/Mst2lckDKO  thy-
mocytes (like Mst1-null naive T cells; 
Zhou et al., 2008) showed a marked 
hyperproliferation in vitro in response 
to anti-CD3 (not depicted), we sus-
pected  that  such  a  response  might 
entrain an apoptotic outcome in vivo. 
Nevertheless,  labeling  in  vivo  with 
BrdU (Lucas et al., 1993) revealed no 
differences in the rate of intrathymic 
proliferation between WT and Mst1/
Mst2lckDKO thymocytes (Fig. 5 E), 
leaving the mechanism underlying their 
exaggerated apoptosis unresolved.
In addition to their defective thymic egress, Mst1/Mst2-
deficient SP T cells were also incapable of entering SLOs 
when placed directly in the circulation. 24 h after i.v. injec-
tion of identical numbers of CD4+ SP thymocytes from WT 
and Mst1/Mst2vavDKO mice into WT recipients, only cells 
from the WT donor were present in peripheral LNs, whereas 
80–90% of the circulating donor T cells were from the Mst1/
Mst2vavDKO donor (Fig. 6 A, top). To assess the localization 
We next examined thymic egress directly, labeling thymo-
cytes in vivo by intrathymic injection of WT, Mst1-null, and 
Mst1/Mst2lckDKO mice with FITC. After 24 h, the numbers 
of FITC-labeled CD4+ and CD8+ SP cells in the circulation, 
spleen, and LNs were quantitated (Fig. 5 C). As compared 
with WT mice, the egress of T cells from the thymus after 
24 h in the Mst1-null mice was reduced by 50 (CD4+) to 65% 
(CD8+), confirming the earlier findings (Dong et al., 2009), and 
Figure 3.  Thymic structure and some 
phenotypes of DP and SP thymocytes from 
WT and Mst1/Mst2vavDKO mice. Genotypes 
are as in Fig. 1. (A) Extracts of CD4+/CD8+, 
CD4+/CD8, and CD4/CD8+ thymocytes from 
WT mice were immunoblotted with antibodies 
indicated as in Fig. 1. (B) Immunoblots of 
extracts from CD4+/CD8+, CD4+/CD8, and 
CD4/CD8+ thymocytes from WT and Mst1/
Mst2vavDKO mice. T12 followed by P indi-
cates phosphorylation. (C) Representative 
sections of thymus from WT, Mst1 KO, Mst2 
KO, and Mst1/Mst2vavDKO mice stained 
with hematoxylin and eosin (H&E) or with 
immunofluorescent anti-CD4 and pan-
cytokeratin antibodies. The dashed white 
line shows the demarcation between cortex 
and medulla seen in the hematoxylin and 
eosin stain.JEM Vol. 209, No. 4 
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thymocytes that peaked at 2–5 min (Fig. 8 A) and returned 
toward baseline by 10 min (not depicted); this response was 
substantially reduced in Mst1-null thymocytes and lost en-
tirely in the Mst1/Mst2vavDKO thymocytes (Fig. 8 A). We 
surveyed a variety of other ligands for their ability to promote 
rac1 GTP charging in thymocytes; in addition to CCL19, 
substantial increases in rac1 GTP charging were also seen in 
response to CCL21, CCL17, and SDF1 and more modestly 
with CCL25. None of these ligands promoted rac1 GTP 
charging in the Mst1/Mst2vavDKO CD4+ SP thymocytes 
(Fig. 8 B). We did not detect an increase in rac1 GTP charg-
ing in response to S1P (Fig. 8 B) but did observe a robust 
S1P-induced increase in rhoA GTP charging (Fig. 8 C), as 
previously reported (Stam et al., 1998); this response was   
reduced in the Mst1-null thymocytes and entirely absent in 
Mst1/Mst2vavDKO thymocytes. Thus, elimination of Mst1 
and Mst2 disables the ability of S1P and a variety of chemo-
kine receptors to activate GTP charging of rac1 and rhoA. 
The ability of these ligands to promote Mob1A/B phosphory-
lation, a reflection of Mst1/Mst2 activation, was lost in par-
allel (Fig. 8 D). Notably, these ligands did not promote the 
phosphorylation of Foxo1/3 (Fig. 8 E) or Lats1/2 (Fig. 8 F, 
left) at sites known to be phosphorylated by Mst1 or Mst2, 
nor  was the  phosphorylation of  FoxO1/3 (Fig.  8 E)  and 
Lats1/2 (Fig. 8 F) in thymocytes altered by deletion of Mst1 
and Mst2. Finally, the ability of CCL19 and SDF-1 to acti-
vate p44Erk and p38 (Fig. 8 E) and the ability of H2O2 to 
stimulate Lats1/2 phosphorylation (Fig. 8 F, right) was simi-
lar in WT and Mst1/Mst2-deficient CD90.2+ thymocytes.
Mob1A/B phosphorylated by Mst1 or Mst2 binds  
and activates the Dock8 rac1 guanyl nucleotide  
exchange factor (GEF)
The marked deficits in the ability of several chemokines and 
S1P to activate rac1 and rhoA, respectively, to polarize the 
actin cytoskeleton, and to promote the migration in vitro of 
Mst1/Mst2-deficient SP thymocytes certainly contribute to 
the inability of these cells to emigrate to the thymus in vivo 
and, once in the circulation, to enter LNs. It is highly likely, 
based on the ability of WT but not kinase-inactive Mst1 to 
correct these abnormalities, that these deficits arise from 
the failure of phosphorylation of one or more Mst1/Mst2 
polypeptide substrates. As shown above (Fig. 8, E and F), 
deletion of Mst1 and Mst2 eliminates thymocyte Mob1A/B 
phosphorylation without affecting Lats1/2 or FoxO1/3 phos-
phorylation. Consequently, we focused on Mob1A/B, seek-
ing proteins that, like Lats1/2 and ndr1/2, associate with the 
noncatalytic Mob1A/B polypeptides in a phosphorylation-
dependent manner. Overexpression of Mob1B in 293T cells 
retrieved endogenous Lats1, ndr2 (both known physiological 
partners of Mob1), and equal amounts of Dock6 and Dock7, 
rho family GEFs (Meller et al., 2005; Côté and Vuori, 2007). 
11 members of the Dock family of GEFs occur in mouse 
and man, divided into four subfamilies (A–D) based on amino 
acid sequence alignment; Dock6, Dock7, and Dock8 form 
subfamily C. All Dock proteins are 200 kD and contain 
of the infused WT and Mst1/Mst2 DKO thymocytes re-
siding in the spleen, in a separate experiment, we infused 
CD45.2+ WT/Lck-cre and Mst1/Mst2lckDKO SP thymo-
cytes into CD45.1 recipients. Spleens were removed 24 h 
later and stained with anti-CD45.2 and anti-B220 (the latter 
to define white pulp), and the number of CD45.2+ cells in 
white pulp and in similar sized areas of red pulp was counted 
(a total of 1,500 cells of each genotype). The percentage of 
total Mst1/Mst2 DKO CD45.2+ cells within the CD45.1+ 
recipient splenic follicles was diminished by 70% as com-
pared with the WT CD45.2+ donors (Fig. 6 D). Thus, the 
Mst1/Mst2 DKO SP thymocytes are greatly deficient in 
their ability to enter splenic white pulp. Cell loss, probably 
caused by apoptosis, was a second factor contributing to low 
number  of  Mst1/Mst2lckDKO  SP  thymocytes  recovered   
after i.v. injection. By 1 h after i.v. infusion, the fractional re-
covery of infused Mst1/Mst2lckDKO SP thymocytes from 
blood and SLOs was only about half that of WT or Mst1-null 
SP thymocytes, which were comparable (Fig. 6 E). The abil-
ity of Mst1-null SP thymocytes to enter LNs was also inferior 
to that of WT cells (Fig. 6 B) but markedly superior to that 
of the Mst1/Mst2vavDKO SP thymocytes (Fig. 6 C). Thus, 
despite normal or enhanced expression of the major receptors 
that govern thymic egress (i.e., S1pr1) and entry into SLOs 
(CCR7), T cells deficient in Mst1 and Mst2 are almost en-
tirely unable egress the thymus or enter SLOs.
Deficiency of Mst1 and Mst2 disables S1P  
and chemokine-induced chemotaxis, actin polarization,  
and activation of rho family GTPases in SP thymocytes
Emigration of SP thymocytes to the periphery requires the 
ability to migrate in response to the much higher level of S1P 
in blood (Drennan et al., 2009). The migration in vitro of WT 
CD4+ and CD8+ thymocytes toward S1P at 10 and 100 nM 
increased progressively, but at 1 µM, S1P did not differ 
from baseline levels, likely reflecting down-regulation of the 
receptor S1pr1 (Fig. 7 A); a similar desensitization occurred 
with S1P-stimulated Mob1A/B phosphorylation (Fig. 7 B). 
Compared with WT thymocytes, migration toward S1P was 
unaltered  in  Mst2-null  thymocytes,  slightly  diminished  in 
Mst1-null thymocytes, but virtually eliminated in the Mst1/
Mst2vavDKO SP thymocytes (Fig. 7 A). The loss of the che-
motactic migratory response in the Mst1/Mst2vavDKO thy-
mocytes was not restricted to S1P; the migratory response to 
CCL19 and CCL21, which in the Mst1-null SP thymocytes 
was reduced by approximately half, in the Mst1/Mst2vavDKO 
cells was, like the response to S1P, also lost completely 
(Fig. 7 C). The inability of these stimuli to elicit a migratory 
response from Mst1/Mst2vavDKO thymocytes was accom-
panied by the failure of S1P and CCL19 to promote actin 
polarization (Fig. 7 D).
Regulation of the actin cytoskeleton is critically depen-
dent on the localized activation of rho family GTPases (Gomez 
and Billadeau, 2008; Tybulewicz and Henderson, 2009; 
Ward and Marelli-Berg, 2009). CCL19, for example, elicited 
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Figure 4.  Flow cytometric analysis of CD4+/CD8 (CD4SP) and CD4/CD8+ (CD8SP) thymocytes and peripheral T cells from WT, Mst1 KO, 
and Mst1/Mst2vavDKO mice. (A) The expression of S1pr1 was quantified on the CD24lo/Qa-2hi fraction of CD4+/CD8 and CD4/CD8+ thymocytes from 
WT, Mst1 KO, and Mst1/Mst2vavDKO, and WT mice treated with an i.p. injection of either PBS or 10 mg/kg FTY720 24 h prior. The bar graphs show the 
absolute number of CD4+/CD8 (left) and CD4/CD8+ (right) CD24loQa-2hi thymocytes. Each bar represents combined results from three mice of the indi-
cated genotype (*, P < 0.05). Error bars indicate ±SEM. (B) Northern blot of thymic S1pr1 messenger RNA. (C) The abundance of S1pr1 on CD4SPCD24loQa-2hi 
thymocytes from WT and Mst1/Mst2vavDKO mice was analyzed with or without a prior i.p. injection of FTY720 as in A. (D) CD4+/CD8 thymocytes from 
WT mice were compared with those from Mst1 KO or Mst1/Mst2vavDKO mice for the expression of the chemokine receptors, integrins, and developmen-
tal markers indicated. (E) The expression levels of the indicated markers on CD4+ cells from spleen of WT mice were compared with those from Mst1 KO or 
Mst1/Mst2vavDKO mice. Representative profiles are shown.
 
with  Flag-Mob1B  but  was  extensively  colocalized  with 
myr-Flag-Mob1B WT  but  exhibited  no  colocalization 
with myr-Mob1B[Thr12Ala/Thr35Ala] (Fig. 9 D).
We next examined the functional consequence of Mob1B 
binding to Dock8. Mob1B and full-length Dock8 were co-
expressed with rac1 in 293 cells (which lacked Dock8 but 
expressed Dock6 and Dock7), and the extent of rac1 GTP 
charging was estimated by pull-down of rac1 from cell ex-
tracts with the CRIB domain of the PAK1 protein kinase, 
which binds rac1 and cdc42 preferentially when GTP charged 
(Thompson et al., 1998). If endogenous Mob1A/B was 
depleted using RNA interference directed to their 3 untrans-
lated regions, the expression of recombinant Flag-Mob1B 
alone caused a modest increase in rac1 pull-down, likely re-
flecting  the  interaction  of  Flag-Mob1B  with  endogenous 
Dock6/7. Expression of recombinant Dock8 alone also gave 
a modest increase in rac1 pull-down, but coexpression of 
Flag-Mob1B with Dock8 increased rac1 pull-down further 
as compared with vector controls and either alone (Fig. 9 E). 
Thus, the binding of Mob1B to Dock8, which requires 
Mob1B phosphorylation, stimulates the Dock8 GEF activity 
toward rac1.
DISCUSSION
Whereas deletion of Mst2 from the lymphoid compartment 
has no evident effect, the additional deficiency of Mst2 on an 
Mst1-null background causes a marked exacerbation of the 
deficits seen in Mst1-null T cells. Thymocyte development 
appears to proceed normally, probably because of the very 
low abundance and activity of these kinases in DP and devel-
opmentally earlier thymocytes. Nevertheless, the ability of SP 
thymocytes to exit to the circulation, modestly impaired in 
the Mst1-null mouse, is severely inhibited in the Mst1/Mst2 
DKO. As with thymocyte egress, the entry of T cells into 
LNs, which is also moderately impaired in Mst1-null cells, is 
lost  entirely  in  the  Mst1/Mst2-deficient  SP  thymocytes. 
These deficits in the migration of Mst1/Mst2-deficient SP 
thymocytes occur despite normal levels of the integrin LFA-1, 
of the S1P receptor S1pr1, and of multiple chemokine recep-
tors. Rather, the migratory deficits are in large part caused by 
the failure of these receptors to promote the activation of rho 
family GTPases and polarization of the actin cytoskeleton in 
the thymocytes; based on the phenotype of Mst1-deficient 
naive T cells (Katagiri et al., 2006; Zhou et al., 2008, 2009), 
integrin clustering and activation are also likely to be abrogated. 
two conserved domains, the DHR1/CZH1 domain in the 
amino-terminal half of the protein, a C2 type phospholipid-
binding domain thought to contribute to membrane local-
ization, and DHR2 (approximately 1695–2068 aa), which 
contains the nucleotide exchange domain, located near 
the protein carboxy terminus. Neither Dock6 nor Dock7 is 
expressed in lymphoid tissues; however, Dock8 is highly 
expressed in thymus (Tybulewicz and Henderson, 2009), and 
recombinant Dock8 also binds preferentially to phosphory-
lated Mob1 (Fig. 9 A, left). Notably, Dock2, a member of 
Dock subfamily B whose functions in T cells have been 
extensively characterized (Reif and Cyster, 2002), did not 
coprecipitate with Mob1B in the presence or absence of oka-
daic acid (OKA; Fig. 9 A, right). We next examined whether 
Dock8 endogenous to T cells interacts with Mob1A/B in an 
Mst1/Mst2-dependent manner. CD90.2+ thymocytes were 
isolated from WT and Mst1/Mst2lckDKO mice and treated 
with CCL19 for 5 min, and the Dock8 immunoprecipitate 
was immunoblotted for Mob1A/B (Fig. 9 B). CCL19 stim-
ulated the phosphorylation of endogenous Mob1A/B and 
promoted the coprecipitation of Mob1A/B with Dock8 in 
WT but not in Mst1/Mst2lckDKO thymocytes.
Available antibodies do not enable immunoprecipitation of 
Mob1A/B; we therefore created transgenic mice expressing 
Flag-Mob1B and mutated Flag-Mob1B[Thr12Ala/Thr35Ala] 
driven by the human CD2 promoter (de Boer et al., 2003). 
Expression of recombinant Flag-Mob1B WT in thymus 
proved to be far below the level of endogenous Mob1A/B; 
nevertheless, a substantial amount of endogenous Dock8 was 
recovered with Flag-Mob1B and in slightly greater amounts 
from the extract of CCL19-treated cells (Fig. 9 C), whereas 
Dock8 did not coprecipitate with Flag-Mob1B[Thr12Ala/
Thr35Ala]. A further indication of the ability of a Mob1B to 
bind Dock8 in the cell was provided by using a membrane-
bound Mob1B, created by fusing the c-Src amino-terminal 
myristoylation motif to the Flag-Mob1B amino terminus. The 
transiently expressed myr-Flag-Mob1B polypeptide was ex-
tensively membrane localized (Fig. 9 D, third column), as was 
myr-Flag-Mob1B[Thr12Ala/Thr35Ala]. Myr-Flag-Mob1B 
exhibited a marked increase in phosphorylation at the sites 
catalyzed specifically by Mst1/Mst2, as compared with (non-
myristolylated)  Flag-Mob1B  (Fig.  9  D,  immunoblot);  the 
latter was diffusely cytoplasmic (Fig. 9 D, second column). 
Recombinant Dock8, which exhibits a diffuse distribution 
during transient expression, showed a modest colocalization 750 Mst1 and Mst2 control thymocyte egress | Mou et al.JEM Vol. 209, No. 4 
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Figure 5.  Mst1/Mst2lckDKO mice have lymphopenia caused by impaired thymic egress. (A) Representative flow cytometric analyses for CD4 and 
CD4 and cell counts from thymus, blood, spleen, and LNs from Lck-Cre+Mst1+/+Mst2+/+ (WT) and Lck-Cre+Mst1/Mst2ff (Mst1/Mst2lckDKO) mice. Each 
bar represents combined results from three mice of the indicated genotype (*, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) Thymic morphology of Mst1/
Mst2lckDKO mice; a representative section. (C) Egress of FITC-labeled thymocytes in vivo. 24 h after an intrathymic injection of FITC, the thymus, spleens, 
LNs, and peripheral blood from WT, Mst1 KO, and Mst1/Mst2lckDKO mice were analyzed by flow cytometry. The percentage of FITC-labeled CD4+ and 
CD8+ cells emigrating to the thymus was calculated as total number of FITC-labeled CD4+ or CD8+ cells in SLOs and blood divided by total (thymic +  
peripheral) FITC-labeled CD4+ or CD8+ cells from all sites, multiplied by 100. Statistical analyses were performed using the Student’s t test (***, P < 0.001). 
Each bar represents combined results from three mice of the indicated genotype. (D) Ongoing apoptosis events in freshly isolated CD4+/CD8+, CD4+/CD8, 
and CD4/CD8+ thymocytes are estimated from Annexin V–FITC and 7-AAD staining. The bar graph shows the percentage of Annexin V+/7-AAD SP and 
DP thymocytes from three independent experiments (***, P < 0.001). (E) BrdU-labeled cells among the various subsets of thymocytes. Mice received two  
i.p. injections of BrdU at a 4-h interval. The thymus was removed for analysis 1 h after the second injection. Thymocytes were stained with antibodies 
against mouse CD4-PE, CD8-FITC, BrdU-APC, or isotype control IgG-APC. Regions defining six thymocyte subsets were defined, and the percentage of 
each subset in BrdU+ cells is shown (middle). The percentage of BrdU+ cells in each thymocyte subset is shown in the bar graph. Representative profiles 
are shown. Each bar represents combined results from three mice of the indicated genotype. (A and C–E) Error bars indicate ±SEM.
 
contributing thereby to their catalytic activation (Bichsel   
et al., 2004; Hergovich, 2011). We demonstrated that the 
ability of Mob1A/B to bind Lats1/2 and ndr1/2 is strongly 
dependent on Mob1A/B phosphorylation at Thr12 and 
Thr35 by Mst1 and/or Mst2 (Praskova et al., 2008). The 
identification of the Dock-C subfamily of guanyl nucleotide 
exchangers as phosphorylation-dependent Mob1A/B part-
ners unveils a new signaling pathway downstream of Mst1/
Mst2 as well as a previously unrecognized mode of regulation 
of Dock-C family GEFs.
Thymocytes express multiple rac1/2 GEFs, including 
vav1–3, Dock1, Dock2, Dock5, and Dock8 (Tybulewicz 
and Henderson, 2009). The deficiencies in migration, actin 
polarization, and rac GTPase activation seen in the Mst1/
Mst2-deficient thymocytes resemble those seen with dele-
tion of Dock2, a Dock-B subfamily rac1 GEF expressed 
largely in lymphoid tissues (Fukui et al., 2001). Dock2-null 
mice exhibit diminished numbers of T cells in the periph-
ery. T lymphoid progenitor entry (Lei et al., 2009) and 
thymocyte  development,  apart  from  somewhat  impaired 
positive and negative selection (Sanui et al., 2003b), are rel-
atively well maintained in the absence of Dock2; however, 
egress of SP thymocytes from thymic organ culture in re-
sponse to CCL19 is reduced by 95% (Sanui et al., 2003a). In 
addition, entry of Dock2-deficient T cells into SLOs is de-
fective (Fukui et al., 2001). Despite the presence of vav, 
Dock2-deficient  T  cells  exhibit  diminished  chemokine 
activation of rac1 and greatly reduced actin polymerization 
(Fukui et al., 2001). As regards the regulation, Dock2 
appears to require the noncatalytic protein ELMO1 for 
nucleotide exchange in cells (Sanui et al., 2003b). Recruit-
ment by upstream regulators may occur through its amino-
terminal SH3 domain, which binds Crk; the Dock2 DHR1 
domain binds PtdIns3,4,5P3; however, sustained localization 
requires the generation and binding of phosphatidic acid to 
a polybasic region in the DHR2 segment (Nishikimi et al., 
2009). Despite the overlaps in the properties of Dock2- 
and Mst1/Mst2-deficient T cells, we have no evidence that 
Dock2 is regulated downstream of Mst1/Mst2. Moreover, 
the deficiency of peripheral T cells in the Mst1/Mst2 DKO 
is much greater than in Dock2-deficient mice or in thymocytes 
Thymocyte maturation is thought to depend in part on an 
orderly migration of the cells first into the cortex and then 
into the medulla, a migration orchestrated by the coordinated 
expression of chemokines and their receptors. The normal 
maturation of Mst1/Mst2-deficient thymocytes to a state 
resembling recent thymic emigrants found in normal mice 
suggests that chemokine regulation of rho GTPases and actin 
during thymocyte development through the DP stage occurs 
independently of Mst1/Mst2. Thus, among the various de-
fects evident in the Mst1-null T cell compartment that contrib-
ute to the low levels of peripheral naive T cells (i.e., defective 
migration, hyperproliferation, and accelerated apoptosis), defi-
cient migration emerges as the limiting defect with DKO of 
Mst1 and Mst2.
Nevertheless, the high rate of ongoing apoptosis of Mst1/
Mst2-deficient SP thymocytes (Fig. 5 D) is certainly an im-
portant contributor to the deficiency of peripheral T cells. 
The major factors responsible for the excessive apoptosis of 
the Mst1/Mst2-null CD4+ thymocytes are not known, but 
candidates include their inappropriate entry into a prolifera-
tive program (Zhou et al., 2008), the activation of apoptosis 
by the high levels of reactive oxygen species (Choi et al., 
2009), and perhaps some alteration in the components or 
regulation of intrinsic apoptotic pathways.
The  correction  of  the  phenotype  of  Mst1/Mst2  defi-
ciency in the lymphoid compartment by transgenic expres-
sion of WT but not catalytically inactive Mst1 establishes that 
the defects in cell migration and rho GTPase regulation are 
caused by the lack of Mst1/Mst2-catalyzed substrate phos-
phorylation. The absolute dependence of Mob1A/B phos-
phorylation on Mst1/Mst2, in contrast to the minimal impact 
of Mst1 deletion on Lats1/2 (Fig. 8 F) in T cells (Zhou et al., 
2008), impelled us to seek other Mst1/Mst2 substrates as well 
as other phosphorylation-dependent Mob1A/B binders. The 
Mob1A and Mob1B polypeptides are 96% identical, highly 
conserved from yeast to Drosophila to mammals, and best 
known for their ability to bind to the Saccharomyces cerevisiae 
kinase Dbf2 and the Drosophila kinases Lats/Warts (ortholo-
gous to mammalian Lats1/2) and Trc (orthologous to mam-
malian ndr1/2); Mob1A or Mob1B binding promotes the 
autophosphorylation of these kinases on their activation loop, 752 Mst1 and Mst2 control thymocyte egress | Mou et al.JEM Vol. 209, No. 4 
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by the loss of the rac-specific Dock2 or both the rac1 + rac2 
GTPases.  As  regards  the  role  of  Dock8, T  cells  from 
Dock8-deficient mice (Randall et al., 2011) do show some 
commonalities with the Mst1/Mst2-deficient SP thymocytes, 
most notably a failure to polarize LFA-1 or actin to the 
immune synapse. The Dock8-deficient mice also exhibit a 
from rac1ff/rac2ff/lck-cre mice (Faroudi et al., 2010). Some 
of this difference is likely attributable to excessive intrathymic 
and postegress apoptosis in the Mst1/Mst2 DKO thymocytes; 
however, it is clear that the Mst1/Mst2 DKO thymocytes 
lack the ability to activate rhoA as well as rac, and so their 
defect in cytoskeletal regulation exceeds that engendered 
Figure 6.  Differential homing of CD4+/CD8 thymocytes from WT, Mst1-null (1KO), and DKO mice into SLOs. (A–C) Genotypes as in Fig. 1. 
Representative flow cytometric profiles of a 50:50 mixture of CMF2HC (blue)- or CMFDA (green)-labeled CD4+/CD8 thymocytes from WT and DKO mice 
(A), WT and Mst1 KO mice (B), and Mst1 KO and DKO mice (C) are shown before injection (BI) and when sampled from blood (PBL), spleen, axillary LNs 
(ALN), and mesenteric LNs (MLN) at 1 and 24 h after i.v. injection. The bar graphs show the ratios of labeled cells before injection and in lymphoid tissues 
as indicated; LNs including axillary (ALN), brachial (BLN), caudal (CLN), pancreatic (PLN), mesenteric (MLN) and inguinal (ILN) LNs. Data were pooled from 
three independent experiments. Each bar in A–C represents combined results from three mice of the indicated genotype. (D) The fraction of injected cells 
in the spleen residing in B cells follicles, as described in Materials and methods. CD45.2 is an alloantigen of CD45 expressed in all donor but not in recipi-
ent lymphoid cells. Data are combined from three independent experiments. Comparisons between WT and Mst1-null mice and WT and DKO mice were 
performed using the Student’s t test (**, P < 0.01). (E) The relative recovery of dye-labeled cells in SLOs at 1 and 24 h after injection (**, P < 0.01). Each bar 
represents combined results from three mice of the indicated genotype. (A–E) Error bars indicate ±SEM.
 
Figure 7.  Chemotaxis and actin polarization are greatly inhibited in Mst1/Mst2-deficient thymocytes. (A and C) Thymocyte migration to S1P. 
Genotypes of WT and DKO as in Fig. 1. WT, Mst1-null (Mst1 KO), Vav-Cre+Mst2ff (Mst2 KO), and DKO thymocytes (106) were placed in the upper well; after 
3 h, the upper and lower wells were analyzed by flow cytometry for the number CD4+/CD8 cells. The fraction migrating to the lower well in response to 
S1P (A) at the concentrations shown or to CCL19 and CCL21 at 200 ng/ml (C) was calculated. The result of triplicate analyses is shown; a second experi-
ment gave similar results. Comparisons were performed using the Student’s t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Error bars indicate ±SEM. 
(B) A time course of S1P-stimulated Mob1A/B (T12) phosphorylation in WT thymocytes. (D) Actin polarization in CD90.2 thymocytes from WT and DKO 
mice 2 min after the addition of 0.1 µM S1P or 200 ng/ml CCL19. Data are representative of three experiments.754 Mst1 and Mst2 control thymocyte egress | Mou et al.
Figure 8.  Thymocyte signaling in response to chemokines and S1P. (A) The effect of CCL19 on rac1 GTP charging in WT, Mst1 KO, and DKO CD4 SP 
thymocytes; genotypes of WT and DKO as in Fig. 1. Cells were extracted before (open bars) and at 2 min after (closed bars) treatment with 200 ng/ml 
CCL19. Rac1 GTP charging was measured using a G-LISA kit (Cytoskeleton) according to manufacturer’s instructions and read as absorbance at 490 nm 
(**, P < 0.01 WT at 2 min vs. at 0 min; ++, P < 0.01 WT vs. 1KO at 2 min ; xx, P < 0.01 WT vs. DKO at 2 min). (B) Rac1 GTP charging was measured as in A 
before and 2 min after the addition of the agents indicated to WT (open bars) or Mst1/Mst2 DKO (closed bars) thymocytes (*, P < 0.05; **, P < 0.01 WT at 
2 min vs. at 0 min; +, P < 0.05; ++, P < 0.01 WT vs. DKO at 2 min). (C) The effect of 0.1 µM S1P (2 min) on rhoA GTP charging in WT, Mst1 KO, and Mst1/
Mst2 DKO CD4 SP thymocytes. RhoA GTP charging was measured using a G-LISA kit (**, P < 0.01 WT at 2 min vs. at 0 min; ++, P < 0.01 WT vs. 1KO at  
2 min; xx, P < 0.01 WT vs. DKO at 2 min). Each bar in A–C represents combined results from three mice of the indicated genotype. Error bars indicate ±SEM. 
(D) Effect of 200 ng/ml CCL21, 0.1 µM S1P, and 1 µg/ml anti-CD3 antibody on Mob1(T12) phosphorylation in thymocytes. (E) The effect of 200 ng/ml 
CCL19 (left) and 100 ng/ml SDF1 (right) on Mob1A/B(T12), p44erk, p38, and Foxo1/3(S212) phosphorylation in thymocytes. The bottom panel shows poly-
peptide abundance. (F) The effect of 200 ng/ml CCL19, 100 ng/ml SDF1, and 50 ng/ml PMA on the phosphorylation of Lats1/2 and Yap1 in thymocytes.
50% decrease in peripheral naive T cells without fewer SP 
thymocytes or evidence of disturbed thymic differentiation. 
In reconstitution of irradiated mice with mixtures of WT 
and Dock8 mutant bone marrow, Dock8 mutant T cells 
contributed only 5% of circulating T cells, whereas thymic 
engraftment of Dock8 mutant cells ranged from 30% to JEM Vol. 209, No. 4 
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phenotypes of the Mst1/Mst2-deficient thymocytes. Deficient 
Dock8 GEF activity is unlikely to underlie the failure of S1P 
activation of rhoA or the accelerated apoptosis, so that other 
Mst1/Mst2 or P-Mob1A/B effectors remain to be uncovered. 
However, it is likely that the loss of Mob1A/B binding to 
Dock8 contributes to the failure of chemokine-stimulated 
rac1 activation in Mst1/Mst2-deficient thymocytes and in 
turn to the failure of thymic egress. Moreover, the identifica-
tion of Mst1/Mst2 regulation of Dock8 through Mob1A/B 
22% to 16% of WT numbers for double-negative, DP, and 
SP thymocytes, respectively. Dock8-deficient humans ex-
hibit a hyper-IgE form of combined immunodeficiency with 
low numbers of T and B cells and susceptibility to cutaneous 
viral infections and tumorigenesis, pointing to defective T cell 
function (Engelhardt et al., 2009; Zhang et al., 2009). Given 
the limited overlap between Dock8 and Mst1/Mst2 deficiency, 
it is clear that the loss of phospho-Mob1A/B activation of 
Dock8 can only be one of several factors contributing to the 
Figure 9.  Mob1A/B phosphorylated by Mst1/Mst2 binds and regulates Dock8 but not Dock2. (A) Dock8 but not Dock2 binds specifically to 
phospho-Mob1. U2OS cell lines stably expressing Flag-Mob1B WT or Flag-Mob1B[Thr12Ala/Thr35Ala] were transfected with HA-Dock8 or HA-Dock2. After 
48 h, OKA or carrier was added for 30 min. The Flag-Mob1 immunoprecipitates were probed for Flag-Mob1B, Mob1(T12P), and HA-Dock8 or -Dock2. 
(B) CCl19 stimulates the Mst1/Mst2-dependent coprecipitation of Dock8 and Mob1A/B(T12) phosphorylation in mouse thymocytes. WT and DKO (geno-
types as in Fig. 1) CD90.2+ thymocytes were treated with 250 ng/ml CCL19 or carrier for 5 min before extraction, and immunoprecipitations (IP) were 
performed using rabbit anti-Dock8. (C) Transgenic thymic Flag-Mob1B WT but not Flag-Mob1B[Thr12Ala/Thr35Ala] coprecipitates endogenous Dock8. 
Thymocytes from mice expressing Flag-Mob1B WT or Flag-Mob1B[Thr12Ala/Thr35Ala] driven by a CD2 promoter were treated with 250 ng/ml CCL19 or 
carrier for 5 min. Immunoprecipitations prepared with normal IgG or anti-Flag were probed for Dock8, Mob1B(T12P), and Flag-Mob1B. (D) Colocalization 
of Dock8 with Flag-Mob1BWT, Flag-myr-Mob1BWT, and Flag-Mob1B[Thr12Ala/Thr35Ala]. HA-tagged Dock8 was transiently expressed alone or with Flag-
Mob1BWT, Flag-myr-Mob1BWT, and Flag-Mob1B[Thr12Ala/Thr35Ala] in U2OS cells. The proteins were visualized with antibody against Flag and HA, and 
colocalization is shown in yellow. Western blots (below the images) show that at similar levels of total Mob1B polypeptide, Flag-myr-Mob1B WT exhibits 
much higher phosphorylation than nonmyristolylated Flag-Mob1B WT. (E) Mob1B stimulates Dock8 GEF activity. 293T cells were cotransfected with Myc-
rac1 and a vector expressing shRNA against both Mob1A and Mob1B. Some cells also received HA-Dock8, or an RNA interference (RNAi)–insensitive Flag-
Mob1B or both. After 24 h, cell extracts were incubated with an excess of a GST-Pak1-CRIB domain fusion protein, and the GST pull-downs were probed 
for Myc-rac1. The ratio of Myc-rac in the pull-down fraction relative to that in the total lysate of cells receiving only myc-rac1 was set to one; other  
ratios were normalized to this value. Two independent experiments are shown. IB, immunoblot.756 Mst1 and Mst2 control thymocyte egress | Mou et al.
which are 96% identical in amino acid sequence. Mob1A and Mob1B 
are  each  phosphorylated  at  Thr12  and  Thr35  comparably  by  either 
Mst1 or Mst2 (Praskova et al., 2008), and the phospho-specific antibod-
ies  against  the  Mob1A/B  Thr12(PO4)-peptide  and  Thr35(PO4)-peptide, 
CSRSSKT(PO4)FKPKKNamide  and  CLKHAEAT(PO4)LGSGNamide, 
respectively, react similarly with the corresponding phosphorylated forms 
of Mob1A and Mob1B. Therefore, the endogenous polypeptides detected 
on immunoblots of tissue/cell extracts with the anti-Mob1B or the phospho-
specific Mob1A/B antibodies are referred to herein as Mob1A/B.
Generation of transgenic Flag-Mst1[WT], Flag-Mst1[K59R], Flag-
Mob1B[WT],  and  Flag-Mob1B[Thr12Ala/Thr35Ala]  mice  and 
Mst1/Mst2  DKO  mice.  The  CD2-Flag-Mst1  and  CD2-Flag-Mob1B 
transgenic constructs were made by cloning into the EcoRI site of the CD2 
vector (de Boer et al., 2003), a gift from D. Kioussis (Medical Research 
Council National Institute for Medical Research, London, England, UK). 
Two founders each were obtained and bred. Transgenic heterozygote mice 
issued from these founders were studied and compared with nontransgenic 
siblings raised in identical conditions. Genotyping was performed on tail 
DNAs by the following primers: CD2 primer (5-CCCCTAAGAACAG-
CTTTCCA-3), Mst1 primer (5-TGTGGGAGGAGGGTTTGTAG-3), 
and Mob1B primer (5-TTTAGAAGAGCGACTACCAA-3). Mst1/Mst2ff 
mice were generated as described previously (Zhou et al., 2009). Vav-Cre 
and Lck-Cre mice were purchased from the Jackson Laboratory. Mst1-null 
mice with Mst2 deleted in hematopoietic cells and lymphocytes were gener-
ated by breeding Mst1-null/Mst2ff mice with Vav-Cre or Lck-Cre mice. 
When examining Vav-Cre+Mst1-nullMst2ff mice, Vav-Cre+Mst1+/+Mst2+/+ 
mice  were  used  as  controls;  when  examining  Lck-Cre+Mst1-nullMst2ff 
mice, Lck-Cre+Mst1+/+Mst2+/+ mice were used as controls. Animal proto-
cols were approved by the Institutional Animal Care and Use Committee of 
Massachusetts General Hospital. Comparisons were made using littermates.
Cell isolation and Western blotting. CD90.2-positive thymocytes were 
isolated by using Thy1.2 MicroBeads according to the manufacturer’s in-
structions (Miltenyi Biotec). Before CCL19 and SDF-1 stimulation, the 
cells were rested at 37°C for 2–3 h in RPMI 1640 complete medium con-
taining 10% FBS, 25 mM Hepes, 2 mM l-glutamine, 50 M 2-mercaptoethanol, 
1% nonessential amino acid, and 2 mM sodium pyruvate. Cells were lysed 
in ice-cold lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl, pH 
7.4, 10% glycerol, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10 mM 
Na3VO4, complete Mini protease inhibitor mixture tablet (Roche), and 
2 mM PMSF. The extracted proteins were subjected to SDS-PAGE and 
transferred to polyvinylidene fluoride membranes. The following antibodies 
were  used  for  immunoblotting:  anti-YAP,  anti–P-YAP  (Cell  Signaling 
Technology), anti–phospho-p38 (Cell Signaling Technology), anti–phospho-p44 
(Cell Signaling Technology), anti-Foxo3 (Cell Signaling Technology), 
anti–p-Foxo1/3 (Invitrogen), anti-KLF2 (Sigma-Aldrich), and antiactin 
(Sigma-Aldrich). The antibodies against Mst1, Mst2, Nore1b, Lats1, phospho-
Mobkl1A/B (Thr12P), and phospho-Lats1 carboxy terminus have been   
described  previously  (Praskova  et  al.,  2008).  Horseradish  peroxidase–
conjugated secondary antibodies against rabbit or mouse IgG were ob-
tained from Jackson ImmunoResearch Laboratories, Inc. The specific bands 
were visualized using the SuperSignal West Pico/Femto substrate (Thermo 
Fisher Scientific).
Immunofluorescence staining. Immunofluorescence staining of thymus, 
spleen, and LN sections was performed as described previously (Zhou et al., 
2008, 2009). Thymus, spleen, or LNs were harvested and immediately 
frozen in OCT compound (Tissue-Tek). 6-µm-thick sections were cut and 
stored at 80°C until use. All subsequent manipulations were performed 
at room temperature. Sections were air dried overnight, fixed in ice-cold 
acetone for 10 min, air dried briefly, blocked with 5% normal horse serum 
for 20 min, and incubated with the indicated antibodies: anti–CD4-PE, 
anti–B220-FITC, pan-cytokeratin-FITC (BD), and biotin-conjugated anti-
CD45.2 at 1:50 dilution for 2 h. Streptavidin conjugated with Texas red 
(Jackson ImmunoResearch Laboratories, Inc.) was used at 1:1,000 dilution 
phosphorylation uncovers a new aspect of Mst1/Mst2 action 
and a new pathway for the regulation of rho family GTPases.
It is important to emphasize that both the upstream regu-
lation and the outputs of the Mst1/Mst2-Mob1A/B cassette 
in the lymphoid system differ substantially as compared with 
epithelia. The hippo pathway, as first characterized in flies 
and subsequently in mammalian cell culture, is activated by 
cell–cell contact through adhesion receptors and has an anti-
proliferative, proapoptotic output that is mediated primarily 
by a phosphorylation-induced suppression of the prolifera-
tive, antiapoptotic transcriptional outputs of yorkie/Yap1, an 
oncogenic co-activator (Zhao et al., 2007; Pan, 2010; Halder 
and Johnson, 2011). In the canonical hippo pathway as oper-
ating in epithelia, the primary Mst1/Mst2 scaffold and part-
ner is Salvador, which through its SARAH domain binds 
Mst1/Mst2 and through its WW domain binds Lats1/2,   
a Yap1 kinase. The Salvador–hippo–Lats complex is recruited 
to upstream regulators by complexes of Kibra–Merlin–Expanded. 
In contrast, the obligatory partner of Mst1/Mst2 in lymphoid 
cells is Nore1B/Rassf5b/RAPL, that like Salvador, binds 
Mst1/Mst2 through its carboxy-terminal SARAH domain, 
but unlike Salvador does not bind Lats1/2 and is recruited 
to upstream regulators through the ability of its Ras-Rap 
association domain to bind Rap1-GTP generated in response 
to ligand activated receptors (Katagiri et al., 2006; Avruch 
et al., 2009). The ability of Mst1/Mst2 to couple to the Lats1/2 
kinases or other Yap1 kinases in lymphoid cells in response to 
physiological stimuli is minimal (Fig. 8 F; Zhou et al., 2008). 
As regards regulation, Mst1 in mouse liver exists predominantly 
as a constitutively active 36-kD catalytic fragment with 
unrestricted access to the nucleus (Zhou et al., 2009). In 
lymphoid cells, Mst1/Mst2 occur only as full-length poly-
peptides that become activated only in response to ligand 
stimulation  (Zhou  et  al.,  2008,  2009). The  high  rate  of 
apoptosis in the Mst1/Mst2-deficient thymocytes further 
illustrates  the  tissue-specific  variation  in  the  outputs  of 
Mst1/Mst2. As in thymocytes, deletion of Mst1/Mst2 from 
mouse liver also eliminates Mob1 phosphorylation (Zhou 
et al., 2008) and causes high levels of reactive oxygen spe-
cies (Choi et al., 2009); however, in contrast to the high rate 
of thymocyte apoptosis, Mst1/Mst2-deficient hepatocytes 
exhibit a marked resistance to Fas-induced apoptosis (Zhou 
et al., 2009). Thus, apart from Mob1 phosphorylation, the 
consequences of Mst1/Mst2 deficiency need to be established 
in each tissue, as they may not replicate those predicted from 
the canonical hippo pathway or from studies in transformed 
mammalian cells.
MATERIALS AND METHODS
Mob1A/Mob1B nomenclature. A recent change in the nomenclature of 
the Mob polypeptides (Human Gene Nomenclature Database) has caused   
the polypeptide we previously described (Praskova et al., 2008) as MOBKL1A 
(and which has also been called Mob1 and Mob4A) to be renamed Mob1B   
and the polypeptide we previously called MOBKL1B (and which has also 
been called Mob1, Mats1, and Mob4B) to be renamed Mob1A; the new no-
menclature is used herein. Our antibodies raised against human GST-Mob1B   
(previously MOBKL1A) react equally with human Mob1A and Mob1B,   JEM Vol. 209, No. 4 
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FTY720 administration and S1pr1 staining. Mice were given an i.p. 
injection of 100 µl PBS or 100 µl PBS containing 10 mg/kg FTY720. 24 h 
thereafter, thymocytes were isolated and analyzed by flow cytometry. In 
brief, rabbit anti-S1pr1 primary (a gift from J. Cyster, University of Califor-
nia, San Francisco, San Francisco, CA) and biotin-labeled goat anti–rabbit Ig 
secondary (1:50; BD) antibodies were presorbed for at least 15 min in FACS 
buffer containing 4% normal mouse serum. One million thymocytes sus-
pended in 25 µl of flow buffer were incubated with anti-S1pr1 for 1.5 h on 
ice. Cells were washed once with FACS buffer and then stained with 
secondary antibody for 20 min on ice. After washing with flow buffer, cells 
were further stained with Streptavidin-APC for 20 min on ice (1:200 dilu-
tion; Invitrogen) and analyzed by flow cytometry.
Northern blot analysis. Total RNA was extracted from 5 × 106 cells with 
TRIZOL (Invitrogen). 20 µg RNA was separated by electrophoresis in 2% de-
naturing formaldehyde agarose gels and transferred to a nylon membrane (Hy-
bond N; GE Healthcare). RNA was cross-linked to the membranes by UV 
light. After prehybridization, the membrane was hybridized with the full-length 
S1pr1 cDNAs, labeled with 32P by using a random primer DNA labeling kit 
(QIAGEN). The membrane was washed and exposed to radiographic film.
BrdU administration and detection. WT and DKO-Lck mice received 
two i.p. injections of BrdU (1 mg each at 4-h intervals). Thymocytes were 
harvested 1 h after the second injection (Lucas et al., 1993). BrdU incorpora-
tion was detected using the APC BrdU Flow kit (BD). After surface staining, 
cells were fixed and permeabilized with Cytofix/Cytoperm buffer for 
15–30 min on ice and then treated with DNase to expose incorporated BrdU. 
Subsequently, cells were stained with APC-conjugated anti-BrdU antibody 
and then analyzed by FACS.
Cells and chemokines. U2OS cells stably expressing recombinant Flag-
Mob1[WT] or [Thr12Ala/Thr35Ala] were described previously (Praskova 
et al., 2008). The chemokines CCL17, CCL19, CCL21, CCL25, SDF1, and 
S1P were purchased from R&D Systems. Transfection was performed using 
Lipofectamine 2000 (Invitrogen).
Plasmids. For transient expression, a plasmid encoding doxycycline-inducible   
short hairpin RNAs (shRNAs) against both endogenous Mob1A and Mob1B 
was previously described; some versions also contained an shRNA-resistant 
cDNA encoding Flag-Mob1B[WT] or [Thr12Ala/Thr35Ala] (Praskova et al., 
2008). The cDNAs encoding human Dock8 and Dock2 were cloned into the 
EcoRV and XhoI sites of pcDNA3 vector (Invitrogen) with an HA tag   
on the 5 end. The following primers were used during cloning: Dock8 
forward,  5-ATTCGATATCCAATGACACACCTGAACAGC-3;  and 
reverse,  5-ATTACTCGAGTTAGCTGCCCTGTGAC-3;  and  Dock2 
forward,  5-ATTCGATATCCAATGGCCCCCTGGCGCAAA-3;  and 
reverse, 5-ATTACTCGAGTCACAGGTCCGTGGACAGCG-3.
Assay of endogenous rac1/rhoA GTP charging. SP thymocytes were 
rested in RPMI 1640 medium supplemented with 0.1% BSA for 2 h at 
37°C. Medium alone or medium containing the following chemokines   
(final concentration) was added (250 ng/ml CCL17, 250 ng/ml CCL19,   
250 ng/ml CCL21, 250 ng/ml CCL25, 200 ng/ml SDF-1, or 100 nM S1P) 
to 3 × 105 thymocytes and terminated after 2 min. Cell extracts were assayed 
for rac1 or rhoA GTP charging using the absorbance based G-LISA kits 
(Cytoskeleton). The endogenous Rac or Rho GTPase activity is expressed 
as absorbance readings at 490 nm. Experiments are performed in duplicate or 
triplicate; mean values ± SD are shown.
Assay of recombinant rac1/rhoA GTP charging. 293T cells seeded in 
a 100-mm dish with 50% confluence were transfected with the following 
constructs, in combinations as indicated in Fig. 9 E: 6 µg HA-Dock8, 2 µg 
myc-rac1, 2 µg shMob1A + shMob1B, 2 µg shMob1A + shMob1B + Flag-
Mob1A(WT), or 6 µg of empty pCDNA3-HA vector. 48 h after transfection, 
cells were lysed with binding buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
for CD45.2 detection. Sections were rinsed in PBS (three times, 5 min each) 
and mounted with mounting medium (Vectashield). Digital images were 
acquired  by  using  an  epifluorescence  microscope  (Eclipse  800;  Nikon) 
equipped  with  a  charge-coupled  device  camera  (Orca  100;  Hamamatsu 
Photonics). Epifluorescence images were analyzed using IPLab version 3.2.4 
image processing software (Scanalytics) and imported into Photoshop ver-
sion 7.0 (Adobe Systems) for production of the final figures.
Flow  cytometry.  Single  cell  suspensions  of  thymus,  peripheral  blood, 
spleen, or LN were resuspended in PBS with 1% BSA and blocked with 
CD16/CD32 (Fc III/II receptor; BD). The cells were then counted and 
stained with the indicated antibodies. Antibodies were obtained from eBio-
science. Flow cytometry was performed on an LSR-II (BD) and analyzed 
with FlowJo software (Tree Star).
Intrathymic FITC labeling. Intrathymic FITC injections were performed 
as described previously (Dong et al., 2009). In brief, a ventral midline 
incision was made one-third down the sternum to expose the thymus.   
A Hamilton syringe was used to inject 10 µl of a 1 mg/ml FITC solution 
(Sigma-Aldrich). The skin incision was closed with silk sutures, and mice 
were allowed to recover under a heat source. At day 1 after injection, cells 
in the blood, spleen, and LNs were monitored for FITC incorporation.
Cell-labeling CD45.2-positive cells and adoptive transfer. CD4 SP 
thymocytes  were  isolated  and  labeled  with  2  µM  CellTracker  green 
CMFDA  (5-chloromethylfluorescein  diacetate)  or  2.5  µM  CellTracker 
blue  CMF2HC  (4-chloromethyl-6,8-difluoro-7-hydroxycoumarin)  for   
15 min at 37°C according to manufacturer’s instructions (Invitrogen). Two 
million total thymocytes at a 1:1 ratio were injected into the tail vein 
of C57BL6 mice. The labeled CD4 from peripheral blood, spleen, and 
LNs was analyzed separately by flow cytometry 1 and 24 h after injection. 
To define the intrasplenic localization, 106 CD45.2+CD4+ SP thymocytes 
isolated from each genotype were injected into the tail vein of B6.SJL- 
Ptprca/Pepcb/BoyJ mice (The Jackson Laboratory). Spleens and LNs were 
harvested 24 h thereafter and embedded in OCT for frozen section. After 
anti-CD45.2 and B220 staining (to define follicles), the number of CD45.2+ 
cells in six intrafollicular regions and in six similar sized areas of red pulp 
were counted (a total of 1,500 cells of each genotype), and the percent-
age of total CD45.2+ cells in the CD45.1+ recipient spleens that were 
found within splenic follicles was determined.
Chemotaxis assays. Migration assays were conducted as described previ-
ously (Zhou et al., 2008). In brief, 0.5 ml RPMI medium 1640 containing 
200 ng/ml CCL19, CCL21 (R&D Systems), and the indicated concentra-
tion of S1P (Sigma-Aldrich) was added to the lower chamber. One million 
thymocytes in 150 µl of media were then added to the upper chamber of   
5-µm pore, polycarbonate 24-well tissue culture inserts (Costar) and incu-
bated for 3 h at 37°C in 5% CO2. The thymocytes from the input and lower 
chambers  were  counted  and  stained  with  CD4-PE  and  CD8-FITC  for 
FACS analysis. Percentage of migration was calculated for each flow cytometry–
defined subset by dividing the number of that subset in the input into the 
number of cells migrated. All chemotaxis data represent the mean of triplicate 
wells performed in two experiments.
PBL counts. Mice were anesthetized with isoflurane before blood collec-
tion by tail tip transection. Whole-blood samples (200–300 µl) were col-
lected into EDTA blood collection tubes (BD) and analyzed in duplicate on 
a Hemavet 850FS Multi Species Hematology System (Drew Scientific) pro-
grammed with mouse hematology settings.
Measurements of S1P in thymus and serum. Thymus was homoge-
nized with ice-cold lysis buffer, centrifuged, and used for S1P extraction. 
Samples were processed and analyzed by the Lipidomics Analytical Core of 
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